Incyte (INCY) Competitors $69.23 +0.98 (+1.44%) Closing price 04:00 PM EasternExtended Trading$68.68 -0.56 (-0.80%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, ALNY, BIIB, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, and HALOShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership. Which has more risk & volatility, ABBV or INCY? AbbVie has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Is ABBV or INCY more profitable? AbbVie has a net margin of 7.31% compared to Incyte's net margin of 0.48%. AbbVie's return on equity of 412.03% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie7.31% 412.03% 13.11% Incyte 0.48%2.77%1.77% Which has higher earnings and valuation, ABBV or INCY? AbbVie has higher revenue and earnings than Incyte. AbbVie is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B5.97$4.28B$2.3581.08Incyte$4.24B3.16$32.62M$0.32216.34 Does the media favor ABBV or INCY? In the previous week, AbbVie had 83 more articles in the media than Incyte. MarketBeat recorded 112 mentions for AbbVie and 29 mentions for Incyte. AbbVie's average media sentiment score of 0.77 beat Incyte's score of 0.17 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 69 Very Positive mention(s) 9 Positive mention(s) 16 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Positive Incyte 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ABBV or INCY? AbbVie presently has a consensus target price of $211.29, suggesting a potential upside of 10.89%. Incyte has a consensus target price of $74.47, suggesting a potential upside of 7.56%. Given AbbVie's stronger consensus rating and higher probable upside, research analysts plainly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 8 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.81Incyte 1 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.22 Do institutionals and insiders hold more shares of ABBV or INCY? 70.2% of AbbVie shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Comparatively, 17.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryAbbVie beats Incyte on 13 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.21B$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E Ratio216.3520.3628.1519.68Price / Sales3.16302.56437.63100.28Price / Cash123.2842.3835.5357.53Price / Book3.877.768.235.67Net Income$32.62M-$55.11M$3.23B$257.51M7 Day Performance0.74%0.95%-0.01%0.52%1 Month Performance-2.79%8.44%5.61%8.84%1 Year Performance8.17%-2.38%26.52%14.18% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.6752 of 5 stars$69.23+1.4%$74.47+7.6%+6.2%$13.21B$4.24B216.352,617Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionABBVAbbVie4.8383 of 5 stars$187.44-1.0%$211.29+12.7%+11.0%$331.09B$56.33B79.7655,000Trending NewsAnalyst RevisionALNYAlnylam Pharmaceuticals4.1481 of 5 stars$324.13-2.3%$341.91+5.5%+21.4%$42.26B$2.25B-155.092,230News CoverageAnalyst ForecastBIIBBiogen4.9072 of 5 stars$130.13-2.1%$188.48+44.8%-42.5%$19.07B$9.68B12.857,605Trending NewsInsider TradeAnalyst RevisionUTHRUnited Therapeutics4.9873 of 5 stars$290.39-1.4%$386.15+33.0%-10.4%$13.10B$2.88B11.591,305Positive NewsInsider TradeNBIXNeurocrine Biosciences4.4783 of 5 stars$127.88-1.0%$162.00+26.7%-11.0%$12.66B$2.36B43.351,800Trending NewsAnalyst RevisionEXELExelixis4.7568 of 5 stars$44.16-4.3%$43.56-1.4%+95.4%$12.04B$2.17B20.071,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9843 of 5 stars$57.41-0.2%$93.61+63.1%-33.1%$11.01B$2.85B21.343,040Positive NewsAnalyst ForecastEXASExact Sciences4.6736 of 5 stars$52.48-1.6%$70.40+34.1%+12.6%$9.90B$2.76B-9.527,000RGENRepligen4.6647 of 5 stars$124.43-2.4%$172.83+38.9%-3.7%$6.99B$634.44M-276.511,778Positive NewsHALOHalozyme Therapeutics4.8399 of 5 stars$54.22+0.4%$61.90+14.2%+7.7%$6.68B$1.02B14.42390Positive NewsAnalyst Forecast Related Companies and Tools Related Companies AbbVie Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCY Stock Alerts